Top Page
Wellnex Life Ltd
(Sydney:WNX)
Wellnex Life Ltd (WNX) vs. iShares MSCI Australia ETF (EWA)
Wellnex Life Ltd Business Overview & Revenue Model
Wellnex Life Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.63M | 23.63M | 16.93M | 27.89M | 18.61M | 1.20M |
| Gross Profit | 6.88M | 6.88M | -776.00K | 4.75M | 4.50M | -165.00K |
| EBITDA | -6.62M | -6.62M | -10.57M | -6.82M | -6.35M | -18.41M |
| Net Income | -15.60M | -15.60M | -13.74M | -13.85M | -7.45M | -24.69M |
Balance Sheet | ||||||
| Total Assets | 27.84M | 27.84M | 30.92M | 15.04M | 19.61M | 10.42M |
| Cash, Cash Equivalents and Short-Term Investments | 497.00K | 497.00K | 903.00K | 322.00K | 3.18M | 7.78M |
| Total Debt | 5.45M | 5.45M | 10.67M | 6.95M | 7.86M | 9.31M |
| Total Liabilities | 16.59M | 16.59M | 24.86M | 14.45M | 15.25M | 10.67M |
| Stockholders Equity | 11.25M | 11.25M | 6.06M | 594.00K | 4.36M | -249.00K |
Cash Flow | ||||||
| Free Cash Flow | -666.00K | -666.00K | -6.82M | -6.19M | -8.65M | -5.17M |
| Operating Cash Flow | -666.00K | -666.00K | -6.82M | -6.19M | -8.61M | -4.38M |
| Investing Cash Flow | -8.29M | -8.29M | -13.42M | -2.20M | -3.65M | 9.45M |
| Financing Cash Flow | 8.55M | 8.55M | 20.82M | 5.53M | 7.66M | 1.55M |
Wellnex Life Ltd Technical Analysis
Wellnex Life Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
43 Neutral | AU$32.00M | 37.83 | ― | ― | 6.76% | ― | |
43 Neutral | AU$10.49M | -0.30 | -184.71% | ― | 39.53% | 49.99% | |
43 Neutral | AU$7.33M | -0.67 | ― | ― | -21.84% | 79.99% | |
41 Neutral | AU$6.55M | -2.02 | -60.84% | ― | -18.70% | 20.83% | |
38 Underperform | AU$21.00M | -5.17 | -29.43% | ― | 102.21% | 69.47% |
Wellnex Life Ltd Corporate Events
Wellnex Life has disclosed that an Appendix 3Y notice was lodged late due to an administrative oversight during the Christmas–New Year period, while affirming that it understands its ASX disclosure obligations and has processes in place to ensure timely future filings. The company also detailed off-market internal share transfers within entities associated with Homart Group, involving a total of 1,285,409 Wellnex Life shares moved from Homart Group to JYSF Management Pty Ltd and MYLY Management Pty Ltd, and confirmed that Homart Group Pty Ltd and MYLY Management Pty Ltd now have independent boards and are no longer associated with director Jeffrey Yeh, meaning these entities will act independently regarding their Wellnex Life holdings and upcoming ASIC filings will formalise this change in association status.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has announced the cessation of 1.4 million listed options (ASX code WNXAN), which carried an exercise price of $2.50 and expired on 1 January 2026 without being exercised or converted. The expiry of these options reduces the company’s potential future share dilution, effectively simplifying its capital structure and removing a class of derivative securities from its issued capital, with no immediate cash inflow resulting from option exercise.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Ltd has reported positive initial results from its turnaround strategy, focusing on scaling up the Pain Away brand and enhancing contract manufacturing revenues. The company achieved an EBITDA profit of $0.1 million in November, with year-to-date improvements in sales growth and gross margins. The introduction of Pain Away into major retailers like Costco and 7Eleven has boosted sales by 16%, and the company is on track to reach breakeven by Q2 FY2026. The board remains optimistic about further margin improvements and cost reductions in the upcoming quarters.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited, a company listed on the ASX and AIM, announced the results of its 2025 Annual General Meeting, where all resolutions except one were passed. The resignation of Mr. Ruari McGirr from the Board was noted following the failure of his re-election resolution, and the company plans to search for a new non-executive director with European market experience.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited is undergoing a strategic transformation under the leadership of Executive Chairman Ash Vesali, focusing on the global expansion of its ‘Pain Away’ brand and enhancing contract manufacturing services. The company is implementing cost-reduction measures, including streamlining operations and reassessing trade spends, aiming to reduce annual operating costs by up to 40% and achieve cashflow positive performance. These initiatives are intended to strengthen Wellnex’s market position and deliver value to shareholders.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has reached an agreement with former director George Karafotias to repay his loan by April 2026, leading to the withdrawal of a related AGM resolution. Additionally, Vivienne Zhang has resigned from the Board to focus on her role as Chief Financial Officer, with the company deciding not to immediately replace her Board position, reflecting typical ASX governance practices.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has announced an agreement on a repayment schedule for a loan provided by Zack Bozinovski and his wife. The majority of the loan is set to be repaid by April 2026, aligning with the conclusion of Bozinovski’s employment with the company. This development may impact the company’s financial planning and stakeholder relations as it manages its obligations and resources.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited announced that they are working towards finalizing a repayment schedule for a loan provided by Zack Bozinovski and his wife, with an expected conclusion by 7 November 2025. This update indicates ongoing negotiations and potential financial implications for Wellnex, as the company seeks to resolve outstanding financial commitments, which could impact its financial stability and stakeholder confidence.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has announced the cessation of Zlatko (Zack) Bozinovski as a director of the company, effective October 21, 2025. This change in the board of directors may impact the company’s governance and strategic direction, as Bozinovski held significant interests in the company, including 73,812 fully paid ordinary shares and an additional 667,473 shares through ZLJ Pty Ltd.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited, a company listed on the ASX and AIM, announced the resignation of Mr. Zack Bozinovski as Director and CEO. During the transition period, Executive Chairman Mr. Ash Vesali will manage the company’s daily operations while a search for a new CEO is underway. Additionally, the company has agreed on a repayment schedule for a loan of A$2.3 million from Mr. Bozinovski and his wife, with full repayment due by April 2026.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited, a company listed on ASX and AIM, has announced the resignation of Mr. Zack Bozinovski as Director and Chief Executive Officer. During the transition period, Executive Chairman Mr. Ash Vesali will manage the company’s operations while a new CEO is sought. Additionally, the company has agreed on a repayment schedule for a loan of A$2.3 million received from Mr. Bozinovski and his wife, with full repayment due by April 2026.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Ltd has announced a strategic update under the leadership of new Executive Chairman Ash Vesali, focusing on a two-pillar strategy to enhance shareholder value through profitable growth. The company plans to prioritize its Pain Away brand and expand its contract manufacturing operations while deprioritizing non-core assets. A targeted cost reduction program is expected to deliver over $1 million in annualized savings, positioning Wellnex for sustained positive cash flow and profit.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited reported a decrease in sales and cash receipts for Q1 FY26, primarily due to delayed IP licensing revenue. The company secured additional debt funding and is undergoing an internal review to enhance operational efficiencies and cost savings. Wellnex is exiting the medicinal cannabis market, which contributed minimally to revenue, to focus on more profitable areas.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.